GeneDx Holdings Corp. Class A Common Stock (WGS)

FairStock Score: 33/100 — RISKY

Key Financials

Strengths

• Generates $4 million in annual free cash flow (0.2% yield on market cap)
• Revenue growth of 26.5% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Weak Piotroski F-Score of 2/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

GeneDx Holdings Corp. Class A Common Stock is a micro-cap healthcare company valued at $1.9 billion. Revenue stands at $443 million, though the company is currently unprofitable. From a quality standpoint, GeneDx shows weak Piotroski F-Score of 2/9 signaling deteriorating fundamentals and Altman Z-Score of 2.1 in the grey zone. Growth dynamics show revenue growing at 26.5% and profit growth of -424.9%. Our composite FairStock Score of 33/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

GeneDx's 27% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $4 million in annual free cash flow (0.2% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer